Premature menopause associated with 40% heightened risk of coronary heart disease
According to the US Centers for Disease Control and Prevention, heart disease is the leading cause of death in the…
All articles by GlobalData Healthcare
GlobalData Healthcare
-
-
German study shows promising results for online depression counselling
Clinical depression represents a major public health challenge whose diagnosis and treatment are frequently hindered by social stigma or patient…
-
ACC 2026: Ventyx’s VTX3232 Phase IIa results show anti-inflammatory benefits in obesity
On 30 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana,…
-
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
On 28 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana,…
-
Meningitis outbreak in UK suggests vigilance is required even if cases are rare
The UK is currently facing a meningitis outbreak, especially in the younger population. The outbreak started in Kent, south-east of…
-
ACC 2026: pooled analysis supports early dapagliflozin use in acute HF care
On 30 March, at this year’s American College of Cardiology (ACC) Scientific Session, during a poster contributions session on the…
-
Ayahuasca-derived DMT study shows positive effects on depression therapy in trials
Interest in psychedelic medicines has accelerated in recent years, and new research focusing on dimethyltryptamine (DMT), the main psychoactive compound…
-
2025 dominated in ALS research
Amyotrophic lateral sclerosis (ALS) is a progressive disorder that affects motor neurons responsible for controlling voluntary muscle movement. As these…
-
New Phase II safety data supports enpatoran’s move to Phase III for cutaneous lupus
At SLEuro 2026, Merck KGaA (Merck; known as EMD Serono in the US and Canada) presented new safety and tolerability…
-
Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth
On 20 March, Bristol Myers Squibb (BMS) announced that the FDA granted approval for Opdivo (nivolumab), an immune checkpoint inhibitor…